Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook [Yahoo! Finance]
Goldman Sachs Group, Inc. (The) (GS)
Last goldman sachs group, inc. (the) earnings: 4/15 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
goldmansachs.com/investor-relations
Company Research
Source: Yahoo! Finance
TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and set a price target of $30.50. The upgrade reflected expectations of a catalyst-heavy 2026, supported by renewed assessment of key pipeline assets including Epkinly, Rina-S, and petosemtamab. The firm highlighted combined peak sales potential exceeding $5 billion across these programs, supporting a more favorable risk-reward profile. While acknowledging that the expiration of Darzalex royalty revenues is likely to weigh on growth beginning in 2029, it noted that this impact is already largely incorporated into current valuation levels. In the first quarter of 2026, Genmab A/S (NASDAQ:GMAB) reported that global net product sales of DARZALEX (daratumumab), including both intravenous and subcutaneous formulations, totaled $3.964 billion, as disclosed by Johnson & Johnson. Sales were split between $2.208 billion in the United States and $1.756 billion across international markets.
Show less
Read more
Impact Snapshot
Event Time:
GS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GS alerts
High impacting Goldman Sachs Group, Inc. (The) news events
Weekly update
A roundup of the hottest topics
GS
News
- Holcim AG (HCMLY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]Seeking Alpha
- Chinese Export Prices Rise Up To 20% As Iran War Lifts Costs [Yahoo! Finance]Yahoo! Finance
- Ripple Says Spot XRP ETFs Have Reached $1.53 Billion in Assets Since Launch [Yahoo! Finance]Yahoo! Finance
- How The Schindler Holding (SWX:SCHN) Investment Narrative Is Shifting With Recent Analyst Revisions [Yahoo! Finance]Yahoo! Finance
- Good news: Rumors of a K-shaped economy are overblown so far, says Goldman Sachs. Bad news: 2026 is the year it will really bite [Yahoo! Finance]Yahoo! Finance
GS
Earnings
- 4/14/26 - Beat
GS
Sec Filings
- 4/24/26 - Form FWP
- 4/24/26 - Form FWP
- 4/24/26 - Form 424B2
- GS's page on the SEC website